Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder prevalent among women of reproductive age globally. Its pharmacological and therapeutic management has evolved considerably in recent years, reflecting deeper insights into its intricate pathophysiology. Conventional interventions—such as insulin sensitizers, ovulation inducers, and anti-androgens—remain the foundation of treatment, primarily targeting metabolic disturbances and reproductive dysfunctions. However, these options are limited by variable efficacy, adverse effects, and the absence of individualized therapeutic protocols. Recent advances emphasize emerging therapies, including novel drug classes, nutraceutical formulations, and integrated lifestyle interventions that collectively address metabolic, reproductive, and psychological components of the disease. Despite their promise, most new strategies are constrained by insufficient high-quality clinical evidence, overreliance on data extrapolated from non-PCOS populations, and incomplete mechanistic understanding. Current research underscores the necessity for precision medicine—leveraging genetic, molecular, and digital health data—to enable personalized and targeted therapy frameworks. Future progress will hinge on rigorous randomized controlled trials and multidisciplinary collaboration aimed at refining current pharmacological regimens and validating integrative therapies. A multimodal, patient-centered approach that aligns treatment strategies with individual pathophysiological profiles offers the greatest potential to optimize outcomes and manage the complex interplay of hormonal, metabolic, and emotional dimensions of PCOS.